178 related articles for article (PubMed ID: 20368203)
21. Incretin therapies: effects beyond glycemic control.
Mudaliar S; Henry RR
Am J Med; 2009 Jun; 122(6 Suppl):S25-36. PubMed ID: 19464425
[TBL] [Abstract][Full Text] [Related]
22. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of the effect of diabetes type 2 duration on beta cell secretory function and insulin resistance].
Popović L; Zamaklar M; Lalić K; Vasović O
Srp Arh Celok Lek; 2006; 134(5-6):219-23. PubMed ID: 16972409
[TBL] [Abstract][Full Text] [Related]
24. Incretin therapies: effects beyond glycemic control.
Mudaliar S; Henry RR
Eur J Intern Med; 2009 Jul; 20 Suppl 2():S319-28. PubMed ID: 19580951
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
26. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Scheen AJ; Paquot N
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
[TBL] [Abstract][Full Text] [Related]
27. Beta-Cell Function and Its Underlying Mechanism 2015.
Li Y; Wang C; Omar B; Chen L
J Diabetes Res; 2016; 2016():7638120. PubMed ID: 26783538
[No Abstract] [Full Text] [Related]
28. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
van Raalte DH; Verchere CB
Diabetes Obes Metab; 2017 Sep; 19(9):1205-1213. PubMed ID: 28295962
[TBL] [Abstract][Full Text] [Related]
29. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
30. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
[TBL] [Abstract][Full Text] [Related]
31. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
32. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
33. Abnormalities in insulin secretion in type 2 diabetes mellitus.
Guillausseau PJ; Meas T; Virally M; Laloi-Michelin M; Médeau V; Kevorkian JP
Diabetes Metab; 2008 Feb; 34 Suppl 2():S43-8. PubMed ID: 18640585
[TBL] [Abstract][Full Text] [Related]
34. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
[TBL] [Abstract][Full Text] [Related]
35. The importance of beta-cell management in type 2 diabetes.
Standl E
Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
[TBL] [Abstract][Full Text] [Related]
36. Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes.
Xu W; Weng J
J Diabetes; 2013 Sep; 5(3):268-74. PubMed ID: 23551748
[TBL] [Abstract][Full Text] [Related]
37. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test.
Festa A; Williams K; Hanley AJ; Haffner SM
Diabetes; 2008 Jun; 57(6):1638-44. PubMed ID: 18332099
[TBL] [Abstract][Full Text] [Related]
38. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.
Zaccardi F; Webb DR; Yates T; Davies MJ
Postgrad Med J; 2016 Feb; 92(1084):63-9. PubMed ID: 26621825
[TBL] [Abstract][Full Text] [Related]
39. Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes.
Asghar Z; Yau D; Chan F; Leroith D; Chan CB; Wheeler MB
Diabetologia; 2006 Jan; 49(1):90-9. PubMed ID: 16362284
[TBL] [Abstract][Full Text] [Related]
40. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment.
Marchetti P; Dotta F; Lauro D; Purrello F
Regul Pept; 2008 Feb; 146(1-3):4-11. PubMed ID: 17889380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
